EUCTR2010-019556-44-IT进行中(未招募)不适用
Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel groups, international, multicentre safety study with a 5-week open extension period. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female outpatients, -Aged between 18 and 65 years, -Fulfilling DSM-IV TR criteria for Major Depressive Episode of moderate or severe intensity, -Diagnosis documented using the brief structured interview M.I.N.I., -Clinical Global Impression item 1: CGI severity of illness = 4 (= from moderately ill to extremely ill), -Hospital Anxiety and Depression scale (HAD) completed, -Treated with either paroxetine or venlafaxine at therapeutic doses continuously for at least 6 weeks, -Requiring a change in antidepressant treatment due to an insufficient treatment efficacy with or without acceptability problems.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Patient fulfilling DSM-IV-TR criteria for a Major Depressive Episode of mild intensity and/or episode with psychotic features, catatonic features or with duration < 6 weeks, -All types of mood disorder other than Major Depressive Disorder, according to DSM-IV TR criteria, -Patient treated within 2 weeks before selection visit with either paroxetine or venlafaxine, but in association with another antidepressant drug for more than 3 days, -High Suicidality” according to MINI 5.0.0., -Marked suicidal intent and/or suicidal risk for the current episode, according to the investigator`s opinion, -Women of childbearing potential without effective contraception, -Pregnant or breast-feeding women, -Patients treated within the 4 weeks before selection visit with either an antipsychotic or a barbiturate, - Patients treated with a depot antipsychotic within 2 injection-period time before selection visit, -Patient treated within the 2 weeks before selection visit with a benzodiazepine at a dose which is superior to the maximum recommended dosage, -Hepatic impairment.
研究者
相似试验
进行中(未招募)
1 期
Initiation of agomelatine after antidepressant treatment in outpatients suffering Major Depressive Disorder.MedDRA version: 14.0Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersMajor Depressive DisorderEUCTR2010-019556-44-BEInstitut de Recherches Internationales Servier300
进行中(未招募)
1 期
Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder.A 3-week, randomised, double then single-blind, controlled, parallel groups, international, multicentre safety study with a 5-week open extension period.Major Depressive DisorderEUCTR2010-019556-44-FRInstitut de Recherches Internationales Servier300
已完成
3 期
Initiation of agomelatine after antidepressant treatment in outpatients suffering major depressive disorderISRCTN97599615Institut de Recherches Internationales Servier (France)316
进行中(未招募)
不适用
Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder.A 3-week, randomised, double then single-blind, controlled, parallel groups, international, multicentre safety study with a 5-week open extension period.MedDRA version: 12.1Level: PTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2010-019556-44-HUInstitut de Recherches Internationales Servier300
进行中(未招募)
不适用
Initiation of agomelatine after antidepressant treatment in outpatients suffering major depressive disorderMajor Depressive DisorderEUCTR2010-019556-44-PTInstitut de Recherches Internationales Servier300
